Public Health, Disease Prevention & WellnessMetaVia Starts Phase 1 Study of Dual Agonist DA-1726 for ObesityPR NewswireApril 14, 2026April 15, 2026 by PR NewswireApril 14, 2026April 15, 202607 16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults MetaVia Inc. (Nasdaq: MTVA), a clinical-stage...
